304 related articles for article (PubMed ID: 21940664)
1. Structural selectivity of human SGLT inhibitors.
Hummel CS; Lu C; Liu J; Ghezzi C; Hirayama BA; Loo DD; Kepe V; Barrio JR; Wright EM
Am J Physiol Cell Physiol; 2012 Jan; 302(2):C373-82. PubMed ID: 21940664
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
Pajor AM; Randolph KM; Kerner SA; Smith CD
J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
[TBL] [Abstract][Full Text] [Related]
3. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.
Hummel CS; Lu C; Loo DD; Hirayama BA; Voss AA; Wright EM
Am J Physiol Cell Physiol; 2011 Jan; 300(1):C14-21. PubMed ID: 20980548
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
Takasu T; Yokono M; Tahara A; Takakura S
Biol Pharm Bull; 2019; 42(3):507-511. PubMed ID: 30828082
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the transport activity of SGLT2/MAP17, the renal low-affinity Na
Coady MJ; Wallendorff B; Lapointe JY
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F467-F474. PubMed ID: 28592437
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
[TBL] [Abstract][Full Text] [Related]
8. Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes.
Castaneda F; Burse A; Boland W; Kinne RK
Int J Med Sci; 2007 May; 4(3):131-9. PubMed ID: 17505558
[TBL] [Abstract][Full Text] [Related]
9. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
10. D-Glucose-recognition and phlorizin-binding sites in human sodium/D-glucose cotransporter 1 (hSGLT1): a tryptophan scanning study.
Tyagi NK; Kumar A; Goyal P; Pandey D; Siess W; Kinne RK
Biochemistry; 2007 Nov; 46(47):13616-28. PubMed ID: 17983207
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor binding mode and allosteric regulation of Na
Bisignano P; Ghezzi C; Jo H; Polizzi NF; Althoff T; Kalyanaraman C; Friemann R; Jacobson MP; Wright EM; Grabe M
Nat Commun; 2018 Dec; 9(1):5245. PubMed ID: 30532032
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats.
Yamaguchi K; Kato M; Suzuki M; Asanuma K; Aso Y; Ikeda S; Ishigai M
Drug Metab Dispos; 2011 Oct; 39(10):1801-7. PubMed ID: 21712434
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Structure-Activity Relationship of C-Phenyl D-Glucitol (TP0454614) Derivatives as Selective Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitors.
Kuroda S; Kobashi Y; Kawamura M; Kawabe K; Shiozawa F; Hamada M; Shimizu Y; Okumura-Kitajima L; Koretsune H; Kimura K; Yamamoto K; Kakinuma H
Chem Pharm Bull (Tokyo); 2020; 68(7):635-652. PubMed ID: 32611999
[TBL] [Abstract][Full Text] [Related]
14. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
15. Sodium-independent low-affinity D-glucose transport by human sodium/D-glucose cotransporter 1: critical role of tryptophan 561.
Kumar A; Tyagi NK; Goyal P; Pandey D; Siess W; Kinne RK
Biochemistry; 2007 Mar; 46(10):2758-66. PubMed ID: 17288452
[TBL] [Abstract][Full Text] [Related]
16. A fluorescence method for measurement of glucose transport in kidney cells.
Blodgett AB; Kothinti RK; Kamyshko I; Petering DH; Kumar S; Tabatabai NM
Diabetes Technol Ther; 2011 Jul; 13(7):743-51. PubMed ID: 21510766
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the human Na+-dependent glucose cotransporter hSGLT2.
Ghezzi C; Wright EM
Am J Physiol Cell Physiol; 2012 Aug; 303(3):C348-54. PubMed ID: 22673616
[TBL] [Abstract][Full Text] [Related]
18. Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter.
Hiraizumi M; Akashi T; Murasaki K; Kishida H; Kumanomidou T; Torimoto N; Nureki O; Miyaguchi I
Nat Struct Mol Biol; 2024 Jan; 31(1):159-169. PubMed ID: 38057552
[TBL] [Abstract][Full Text] [Related]
19. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
20. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
Nagata T; Suzuki M; Fukazawa M; Honda K; Yamane M; Yoshida A; Azabu H; Kitamura H; Toyota N; Suzuki Y; Kawabe Y
Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1520-33. PubMed ID: 24761001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
